featured
Safety and Efficacy of Deucravacitinib vs Placebo and Apremilast in Patients With Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial
J Am Acad Dermatol 2022 Sep 14;[EPub Ahead of Print], B Strober, D Thaçi, H Sofen, L Kircik, KB Gordon, P Foley, P Rich, C Paul, J Bagel, E Colston, J Throup, S Kundu, C Sekaran, M Linaberry, S Banerjee, KA PappFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.